Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - linagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 500 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin; metformin hydrochloride - film coated tablets - metformin hydrochloride 850 mg; linagliptin 2.5 mg - metformin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. trajenta-duo should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta-duo has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta-duo.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - empagliflozin 10 mg - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use glyxambi is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.1)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi [see warnings and precautions (5.2)]. glyxambi is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an egfr less than 30 ml/min/1.73 m2 . glyxambi is likely to be ineffecti

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin, metformin - diabetes mellitus, type 2 - drugs used in diabetes, - treatment of adult patients with type-2 diabetes mellitus:jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim pharmaceuticals, inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - trijardy xr is a combination of empagliflozin, linagliptin, and metformin hydrochloride (hcl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . limitations of use trijardy xr is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. it may increase the risk of diabetic ketoacidosis in these patients [see warnings and precautions (5.2)] . trijardy xr has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trijardy xr [see warnings and precautions (5.3)]. trijardy xr is contraindicated in patients with: - severe renal impairment (egfr less than 30 ml/min/1.73 m2 ), end-stage renal disease,

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - empagliflozin (unii: hdc1r2m35u) (empagliflozin - unii:hdc1r2m35u), linagliptin (unii: 3x29zej4r2) (linagliptin - unii:3x29zej4r2) - glyxambi is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see clinical studies (14.2)] . however, the effectiveness of glyxambi on reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established. limitations of use glyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis [see warnings and precautions (5.4)] . glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi

Kenya - English - Pharmacy and Poisons Board

linagliptin inn 5mg - tablet - linagliptin inn 5mg - linagliptin

Kenya - English - Pharmacy and Poisons Board

linagliptin inn - film-coated tablet - linagliptin inn 5 mg /tablet - linagliptin

Kenya - English - Pharmacy and Poisons Board

q pharma dmcc unit no: 2681 dmcc business centre level no - linagliptin - tablet - linagliptin 5mg - linagliptin